Exelixis Inc. (EXEL)
NASDAQ
Closed
Oct 9, 2026
Day's Range
59.0052 wk Range
33.76Overview - EXEL - Exelixis Inc.
Key Statistics
Valuation
Enterprise Value
13.79B
P/E (Trailing)
‪18.36‬
P/E (Forward)
‪13.72‬
PEG Ratio
‪0.73‬
Price / Sales (TTM)
‪5.93‬
Price / Book
‪7.88‬
EV / EBITDA
‪13.52‬
Profitability
Gross Margin
‪96.71%‬
Profit Margin
‪35.33%‬
Operating Margin
‪39.51%‬
Return on Assets
‪23.97%‬
Return on Equity
‪44.39%‬
Ownership
Shares Outstanding
248.88M
Float
213.60M
Short % of Shares Outstanding
‪14.56%‬
Held by Insiders
‪1.84%‬
Held by Institutions
‪106.80%‬
Price stats
Beta
‪0.42‬
50-Day Avg
‪55.78‬
200-Day Avg
‪48.99‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
19 analysts
Average price target
‪$ 53.69‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - EXEL - Exelixis Inc.
Peers - EXEL - Exelixis Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- EXELNASDAQExelixis Inc.14.46BMarket Cap+31.34%52-week change18.36P/E (Trailing)‪35.33%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - EXEL - Exelixis Inc.
About
Exelixis Inc. is an oncology-focused biopharmaceutical company that discovers, develops, and commercializes medicines for difficult-to-treat cancers. The company’s current portfolio centers on cancer therapies built around cabozantinib, including CABOMETYX and COMETRIQ, which are used across multiple tumor types in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
